New data from Biogen reveals higher Spinraza doses may enhance motor function in SMA patients. Read more here.

New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who ...

US biotech major Biogen today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of ...

Biogen Inc. (NASDAQ:BIIB) is one of the best S&P 500 stocks with huge upside potential. As of June 16, Biogen emerged as a ...

Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in ...

Biogen is an intriguing stock that occupies one of the leading positions in the central nervous system therapeutic market.

Biogen has pointed to an early readout from a small phase 1 trial as evidence that its antisense oligonucleotide salanersen ...

Biogen Inc. closed 46.93% short of its 52-week high of $238.00, which the company achieved on July 12th.

New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg SP ...

Shares of Biogen Inc. BIIB slipped 1.79% to $124.76 Monday, on what proved to be an all-around positive trading session for ...

In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of $213.00. The company’s shares cl ...

Antisense-based therapy salanersen (BIIB115/ION306) is a possible follow-up to Biogen's big-selling Spinraza (nusinersen) therapy for SMA, which has come under pressure from increased competition in ...